Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$10.1 million.

  • Anika Therapeutics' Income from Continuing Operations fell 69.33% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year decrease of 259.09%. This contributed to the annual value of -$10.1 million for FY2024, which is 194.91% down from last year.
  • Anika Therapeutics' Income from Continuing Operations amounted to -$10.1 million in FY2024, which was down 194.91% from -$3.4 million recorded in FY2023.
  • Anika Therapeutics' 5-year Income from Continuing Operations high stood at $6.7 million for FY2021, and its period low was -$24.0 million during FY2020.
  • Its 3-year average for Income from Continuing Operations is -$4.5 million, with a median of -$3.4 million in 2023.
  • In the last 5 years, Anika Therapeutics' Income from Continuing Operations soared by 127.78% in 2021 and then tumbled by 2,989.92% in 2023.
  • Yearly analysis of 5 years shows Anika Therapeutics' Income from Continuing Operations stood at -$24.0 million in 2020, then skyrocketed by 127.78% to $6.7 million in 2021, then crashed by 98.21% to $119,000 in 2022, then crashed by 2,989.92% to -$3.4 million in 2023, then crashed by 194.91% to -$10.1 million in 2024.